CRISPR tiling screen reveals cancer epigenetic 'Goldilocks' state

Aleksia Barka; Rahul M Kohli; Junwei Shi

doi:10.1016/j.tips.2023.05.007

CRISPR tiling screen reveals cancer epigenetic 'Goldilocks' state

Trends Pharmacol Sci. 2023 Sep;44(9):555-557. doi: 10.1016/j.tips.2023.05.007. Epub 2023 Jun 14.

Authors

Aleksia Barka¹, Rahul M Kohli², Junwei Shi³

Affiliations

¹ Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
² Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: rkohli@pennmedicine.upenn.edu.
³ Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: jushi@upenn.edu.

PMID: 37328396
DOI: 10.1016/j.tips.2023.05.007

Abstract

CRISPR tiling screens offer an efficient way to identify gain-of-function mutations in targets of cancer therapy. Recently, by utilizing these screens, Kwok et al. unexpectedly discovered mutations conferring drug addiction in lymphoma, revealing a requirement for a 'just right' window of histone methylation crucial for cancer survival.

Keywords: drug addiction; drug resistance; lymphoma; methylation index; tiling mutagenesis.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

CRISPR-Cas Systems
Clustered Regularly Interspaced Short Palindromic Repeats* / genetics
Epigenesis, Genetic
Epigenomics
Humans
Neoplasms* / genetics

Abstract

Publication types

MeSH terms

Grants and funding